Elsevier and eMolecules Collaboration Enables Easy Sourcing of Chemicals via Reaxys®
Enriched content offering integrates reaction and substance searching, synthesis planning and chemical procurement into a seamless workflow
Frankfurt, 14 September, 2010 – Elsevier is pleased to announce that Reaxys now provides an enriched commercial availability service, as a result of the ongoing collaboration between the Reaxys development team and eMolecules. Chemical procurement of commercially available compounds is now incorporated into the reaction and substance search workflow. Research chemists can now immediately access the eMolecules ordering page, complete with full quantity, pricing and vendor information, all via the eMolecules icon. It becomes part of the overall research workflow, the chemist can order the desired compound and easily continue with their reaction or substance query.
Reaxys is Elsevier’s web-based chemistry application which combines reaction and substance data search and retrieval in organic, organometallic, inorganic and physical chemistry with synthesis planning. Reaxys allows research chemists to get important and relevant information from journals and patents fast and conveniently in a single overview.
Mark van Mierle, MD of Elsevier Information Systems said, “Sourcing the right chemical at the best price and in an easy manner is clearly a crucial step in a chemist’s workflow. I believe this enhancement to Reaxys will enable chemists to make better decisions and get back to the lab more quickly”
Klaus Gubernator, CEO, eMolecules added, “The collaboration between Elsevier and eMolecules focuses on providing our customers with an enhanced user experience, and the incorporation of all elements of the chemist’s workflow into one integrated system.”
The Reaxys development team will continue to work with eMolecules to further streamline all aspects of the commercial availability process in order to bring the researchers the most relevant information with fewer clicks.
eMolecules is the world's leading open-access chemical structure search engine, providing chemistry eCommerce solutions for suppliers of research chemicals and industrial and academic research organizations. They deliver chemical building blocks and screening compounds worldwide from any supplier in any requested physical format. They are the most popular chemistry web site, distinguished by fast results, ease of use, and up to date information about commercially available chemicals.
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys®, PharmaPendium™, SciVal™ and The Lancet® are owned and protected by Elsevier Properties SA and used under license. For additional information see www.reedelsevier.com.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media Contact
Vice President, Global Corporate Relations